Experimental Smallpox Vaccine Put on Fast Track
The U.S. Food and Drug Administration has awarded “fast track” status to a smallpox vaccine being developed by the pharmaceutical firm Acambis, the company announced today (see GSN, Dec. 10).
The decision means the agency will work to expedite approval of the ACAM2000 vaccine, Acambis said in a press release. More than 180 million doses of the vaccine have been added to the U.S. Strategic National Stockpile for emergency use (Acambis press release, Jan. 5).
The decision means the agency will work to expedite approval of the ACAM2000 vaccine, Acambis said in a press release. More than 180 million doses of the vaccine have been added to the U.S. Strategic National Stockpile for emergency use (Acambis press release, Jan. 5).
